GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XTER:EVT) » Definitions » Valuation Rank

Evotec SE (XTER:EVT) Valuation Rank


View and export this data going back to 1999. Start your Free Trial

What is Evotec SE Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Evotec SE Valuation Rank Related Terms

Thank you for viewing the detailed overview of Evotec SE's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Executives
Dr. Christian Wojczewski Board of Directors
Aurélie Dalbiez Board of Directors
Prof. Dr. Iris Löw-friedrich Supervisory Board
Dr. Craig Johnstone Board of Directors
Dr. Cord Dohrmann Board of Directors
Dr. Werner Lanthaler Board of Directors